Advertisement
Screener

REGENERON PHARMACEUTICALS, INC. (REGN) Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

REGENERON PHARMACEUTICALS, INC. Operating Lease Liability

REGENERON PHARMACEUTICALS, INC. (REGN) had Operating Lease Liability of $266.80 million as of 2025-12-31, per its 10-K filed 2026-02-04.

Financial Statements › Balance Sheet › Liabilities

us-gaap:OperatingLeaseLiability · last filed 2026-02-04

  • 2025-12-31: Operating Lease, Liability $266.80M.
  • 2024-12-31: Operating Lease, Liability $234.40M.
  • 2023-12-31: Operating Lease, Liability $87.70M.
  • 2019-12-31: Operating Lease, Liability $23.60M.
Period endOperating Lease, Liability
2025-12-31$266.80M
10-K · filed 2026-02-04
2024-12-31$234.40M
10-K · filed 2025-02-05
2023-12-31$87.70M
10-K · filed 2024-02-05
2019-12-31$23.60M
10-K · filed 2020-02-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07